Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBIT: 2009-2024

Historic EBIT for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$395.3 million.

  • Iovance Biotherapeutics' EBIT fell 6.55% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$395.3 million for FY2024, which is 14.17% up from last year.
  • As of FY2024, Iovance Biotherapeutics' EBIT stood at -$395.3 million, which was up 14.17% from -$460.6 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year EBIT high stood at -$342.7 million for FY2021, and its period low was -$460.6 million during FY2023.
  • Moreover, its 3-year median value for EBIT was -$398.9 million (2022), whereas its average is -$418.2 million.
  • Its EBIT has fluctuated over the past 5 years, first declined by 16.39% in 2022, then increased by 14.17% in 2024.
  • Yearly analysis of 4 years shows Iovance Biotherapeutics' EBIT stood at -$342.7 million in 2021, then dropped by 16.39% to -$398.9 million in 2022, then declined by 15.46% to -$460.6 million in 2023, then rose by 14.17% to -$395.3 million in 2024.